The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Open accessAbstract
Disease Overview: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B cells. Diagnosis: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B lymphocytes, which identify a clonal B‐cell population carrying the CD5 antigen and B‐cell markers. Prognosis: Two prognostic staging systems exist, the Rai and Binet staging systems, which are established by physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del(17p)) and/or mutations of the TP53 gene predict resistance to available chemotherapies. A comprehensive prognostic score (CLL‐IPI) using genetic, biological, and clinical variables has recently been developed allowing to classify CLL into very distinct risk groups. Therapy: Patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. For physically fit patients, chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab remains the current standard therapy. For unfit patients, currently available evidence supports two options for a first‐line therapy: chlorambucil combined with an anti‐CD20 antibody (obinutuzumab or rituximab or ofatumumab) or a continuous therapy with ibrutinib. At relapse, the initial treatment may be repeated, if the treatment‐free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using alternative agents such as bendamustine (plus rituximab), alemtuzumab, lenalidomide, ofatumumab, ibrutinib, idelalisib, or venetoclax. Patients with a del(17p) or TP53 mutation can be treated with ibrutinib, venetoclax, or a combination of idelalisib and rituximab. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del(17p) or patients that are refractory to chemoimmunotherapy and the novel inhibitors. Future Challenges: The new agents (ibrutinib, idelalisib, venetoclax, and obinutuzumab) hold the potential to significantly improve the outcome of CLL patients. However, their optimal use (in terms of combination, sequence, and duration) remains unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationBinet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v · Cited by 1,778
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationBCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Morton, L. M., Wang, S. S., Devesa, S. S., Hartge, P., Weisenburger, D. D., & Linet, M. S. (2006) · Blood · doi:10.1182/blood-2005-06-2508 · Cited by 1,683
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Self-citationWhole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Self-citationChiorazzi, N., Rai, K. R., & Ferrarini, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041720 · Cited by 1,296
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“Six initial patients with acquired resistance to ibrutinib therapy were examined by whole-exome sequencing.(104) A cysteine-toserine mutation in BTK at the binding site of ibrutinib was found in 5 patients and 3 distinct mutations in PLCgamma2 were identified in 2 patients.”
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“6 months.(101) The most relevant treatment-related side effects were viral infections.”
BackgroundMutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Self-citationFludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez-Trillos, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 996
Comorbidity and functional status are independent in older cancer patients.
Extermann, M., Overcash, J., Lyman, G. H., Parr, J., & Balducci, L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1582 · Cited by 984
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., Ambesi-Impiombato, A., Califano, A., Migliazza, A., Bhagat, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.019 · Cited by 848
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 829
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C.-M., Roberts, A. W., Jurczak, W., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 805
Self-citationRozman, C., & Montserrat, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331606 · Cited by 791
Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
(2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30029-8 · Cited by 672
Eichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Self-citationMonoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Rawstron, A. C., Bennett, F. L., O'Connor, S. J. M., Kwok, M., Fenton, J. A. L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075290 · Cited by 613
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Eichhorst, B. F. (2005) · Blood · doi:10.1182/blood-2005-06-2395 · Cited by 588
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586
Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.218 · Cited by 584
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 561
From pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Thompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2282 · Cited by 484
Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B. V., Larratt, L., Geisler, C. H., Montillo, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4556 · Cited by 480
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationChlorambucil in Indolent Chronic Lymphocytic Leukemia
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382104 · Cited by 447
Knauf, W. U., Lissichkov, T., Aldaoud, A., Liberati, A. M., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranova-Marinova, V. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8389 · Cited by 444
Döhner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W., & Lichter, P. (1997) · Blood · doi:10.1182/blood.v89.7.2516 · Cited by 439
The French Cooperative Group on CLL, Johnson, S., Smith, A. G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P. J., & Hiddemann, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91681-5 · Cited by 434
Fischer, K., Cramer, P., Busch, R., Böttcher, S., Bahlo, J., Schubert, J., Pflüger, K. H., Schott, S., Goede, V., Isfort, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2688 · Cited by 433
Self-citationMoreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.021 · Cited by 419
Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00465-9 · Cited by 415
Self-citationChanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414
Moreau, E., Matutes, E., A’Hern, R., Morilla, A. M., Morilla, R. M., Owusu-Ankomah, K. A., Seon, B. K., & Catovsky, D. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/108.4.378 · Cited by 411
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Ding, W., LaPlant, B. R., Call, T. G., Parikh, S. A., Leis, J. F., He, R., Shanafelt, T. D., Sinha, S., Le-Rademacher, J., Feldman, A. L., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765685 · Cited by 407
Byrd, J. C. (2005) · Blood · doi:10.1182/blood-2004-03-0796 · Cited by 404
Rawstron, A. C., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J. L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404584 · Cited by 403
Self-citationFlinn, I. W., Neuberg, D. S., Grever, M. R., Dewald, G. W., Bennett, J. M., Paietta, E. M., Hussein, M. A., Appelbaum, F. R., Larson, R. A., Moore, D. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0762 · Cited by 402
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 398
Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M., Jaubert, J., Autrand, C., Diviné, M., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2319 · Cited by 391
B-cell receptor signaling in chronic lymphocytic leukemia
Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J., & Packham, G. (2011) · Blood · doi:10.1182/blood-2011-06-338855 · Cited by 390
Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C. D., Böttcher, S., Staib, P., Kiehl, M., Eckart, M. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8061 · Cited by 379
Self-citationThe Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., et al. (2007) · Blood · doi:10.1182/blood-2005-12-051458 · Cited by 348
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., Doubek, M., Panagiotidis, P., Kimby, E., Schuh, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60027-7 · Cited by 343
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Jain, P., Keating, M., Wierda, W., Estrov, Z., Ferrajoli, A., Jain, N., George, B., James, D., Kantarjian, H., Burger, J., et al. (2015) · Blood · doi:10.1182/blood-2014-09-603670 · Cited by 334
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
(1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.861 · Cited by 328
Levels of expression of CD19 and CD20 in chronic B cell leukaemias.
Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., & Catovsky, D. (1998) · Journal of Clinical Pathology · doi:10.1136/jcp.51.5.364 · Cited by 325
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Maloney, D. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1114348 · Cited by 322
Kikushige, Y., Ishikawa, F., Miyamoto, T., Shima, T., Urata, S., Yoshimoto, G., Mori, Y., Iino, T., Yamauchi, T., Eto, T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.029 · Cited by 317
Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 307
Dreger, P., Döhner, H., Ritgen, M., Böttcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275420 · Cited by 305
Self-citationO'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Bociek, R. G., Pavletic, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1191 · Cited by 303
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine
Anaissie, E. J., Kontoyiannis, D. P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-7-199810010-00010 · Cited by 297
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., Bauer, K., Malchau, G., Rabe, K. G., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556399 · Cited by 283
Self-citationChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Hallek, M. (2015) · American Journal of Hematology · doi:10.1002/ajh.23979 · Cited by 263
Self-citationFaderl, S., Thomas, D. A., O'Brien, S., Garcia-Manero, G., Kantarjian, H. M., Giles, F. J., Koller, C., Ferrajoli, A., Verstovsek, S., Pro, B., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1952 · Cited by 251
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
Pedersen, I. M., Kitada, S., Leoni, L. M., Zapata, J. M., Karras, J. G., Tsukada, N., Kipps, T. J., Choi, Y. S., Bennett, F., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v100.5.1795.h81702001795_1795_1801 · Cited by 248
Petlickovski, A., Laurenti, L., Li, X., Marietti, S., Chiusolo, P., Sica, S., Leone, G., & Efremov, D. G. (2005) · Blood · doi:10.1182/blood-2004-07-2669 · Cited by 245
Tsukada, N., Burger, J. A., Zvaifler, N. J., & Kipps, T. J. (2002) · Blood · doi:10.1182/blood.v99.3.1030 · Cited by 226
Robak, T., Błoński, J. Z., Kasznicki, M., Błasińska-Morawiec, M., Krykowski, E., Dmoszyńska, A., Mrugala-Śpiewak, H., Skotnicki, A. B., Nowak, W., Konopka, L., et al. (2000) · PubMed · doi:10.1182/blood.v96.8.2723.h8002723_2723_2729 · Cited by 218
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 217
Stilgenbauer, S., & Döhner, H. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470619 · Cited by 216
Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinköthe, T., Stützer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9950 · Cited by 209
Self-citationSchulz, H. (2002) · Blood · doi:10.1182/blood-2002-03-0972 · Cited by 204
Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., Loscertales, J., Taylor, K., Vandenberghe, E., Wach, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30019-4 · Cited by 202
Dreger, P., Schetelig, J., Andersen, N., Corradini, P., van Gelder, M., Gribben, J., Kimby, E., Michallet, M., Moreno, C., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586826 · Cited by 199
Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198
CHLORAMBUCIL IN INDOLENT CHRONIC LYMPHOCYTIC LEUKEMIA
Ighiero, G. U. D., Aloum, K., Ernard, B., Azin, B. R. C., Avarro, M. A. N., Eblay, R. O. L., Eporrier, M. I. L., Aubert, J., Epeu, G. É. L., Inet, B., et al. (1998) · Cited by 192
Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G., & Hillmen, P. (2002) · Blood · doi:10.1182/blood.v99.6.2245 · Cited by 186
The triterpenoid CDDO induces apoptosis in refractory CLL B cells
Pedersen, I. M., Kitada, S., Schimmer, A., Kim, Y., Zapata, J. M., Charboneau, L., Rassenti, L., Andreeff, M., Bennett, F., Sporn, M. B., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1174 · Cited by 183
Bosch, F., Ferrer, A., López‐Guillermo, A., Giné, E., Bellosillo, B., Villamor, N., Colomer, D., Cobo, F., Perales, M., Esteve, J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03959.x · Cited by 181
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Cited by 180
Kovacs, G., Robrecht, S., Fink, A. M., Bahlo, J., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Fingerle-Rowson, G., Ritgen, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1305 · Cited by 175
Self-citationPrognostic factors in chronic lymphocytic leukemia—what do we need to know?
Cramer, P., & Hallek, M. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.167 · Cited by 173
Self-citationZenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.208 · Cited by 169
Self-citationO'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A. B., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Gribben, J., Itri, L. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.5748 · Cited by 167
Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment
Hallek, M. J. (2013) · American Journal of Hematology · doi:10.1002/ajh.23491 · Cited by 159
Self-citationBadoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158
Cartron, G., de Guibert, S., Dilhuydy, M., Morschhauser, F., Leblond, V., Dupuis, J., Mahé, B., Bouabdallah, R., Lei, G., Wenger, M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586610 · Cited by 157
Self-citationEmerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Wiestner, A. U. (2012) · Blood · doi:10.1182/blood-2012-05-423194 · Cited by 153
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Plunkett, W., Gandhi, V., Huang, P., et al. (1993) · PubMed · Cited by 150
Patz, M., Isaeva, P., Forcob, N., Müller, B., Frenzel, L. P., Wendtner, C., Klein, C., Umaña, P., Hallek, M. J., & Krause, G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08428.x · Cited by 149
Self-citationNovel CD20 monoclonal antibodies for lymphoma therapy
Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-64 · Cited by 140
Jaglowski, S. M., Jones, J. A., Nagar, V., Flynn, J. M., Andritsos, L. A., Maddocks, K. J., Woyach, J. A., Blum, K. A., Grever, M. R., Smucker, K. A., et al. (2015) · Blood · doi:10.1182/blood-2014-12-617522 · Cited by 138
Minimal residual disease is an independent predictor for 10-year survival in CLL
Kwok, M., Rawstron, A. C., Varghese, A. M., Evans, P., O’Connor, S. J. M., Doughty, C., Newton, D. J., Moreton, P., & Hillmen, P. (2016) · Blood · doi:10.1182/blood-2016-05-714162 · Cited by 137
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Fischer, K., Al‐Sawaf, O., Fink, A., Dixon, M., Bahlo, J., Warburton, S., Kipps, T. J., Weinkove, R., Robinson, S., Seiler, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761973 · Cited by 119
Self-citationHerman, S. E. M., Mustafa, R. Z., Jones, J. E., Wong, D. H., Farooqui, M. Z. H., & Wiestner, A. U. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0781 · Cited by 116
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Hallek, M. J. (2013) · Blood · doi:10.1182/blood-2013-05-498287 · Cited by 113
Self-citationReinart, N., Nguyen, P., Bouças, J., Rosen, N., Kvasnicka, H. M., Heukamp, L. C., Rudolph, C., Ristovska, V., Velmans, T., Mueller, C., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431452 · Cited by 109
Self-citationIbrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Fiorcari, S., Maffei, R., Audrito, V., Martinelli, S., ten Hacken, E., Zucchini, P., Grisendi, G., Potenza, L., Luppi, M., Burger, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11782 · Cited by 108
Leprêtre, S., Aurran, T., Mahé, B., Cazin, B., Tournilhac, O., Maisonneuve, H., Casasnovas, O., Delmer, A. J., Leblond, V., Royer, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-365437 · Cited by 98
Elter, T., Gercheva, L., Pylylpenko, H., Robak, T., Jaksic, B. S., Rekhtman, G. B., Kyrcz‐Krzemień, S., Vatutin, M. T., Wu, J., Sirard, C. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70242-x · Cited by 97
Self-citationSex differences in incidence and outcome of chronic lymphocytic leukemia patients
Molica, S. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600555819 · Cited by 95
Nguyen, P., Fedorchenko, O., Rosen, N., Koch, M., Barthel, R., Winarski, T., Florin, A., Wunderlich, F. T., Reinart, N., & Hallek, M. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.007 · Cited by 90
Self-citationEfficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Sher, T., Miller, K. C., Lawrence, D. D., Whitworth, A., Hernandez‐Ilizaliturri, F. J., Czuczman, M. S., Miller, A., Lawrence, W., Bilgrami, S. A. A., Sood, R., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903406806 · Cited by 82
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Strati, P., Keating, M. J., Wierda, W. G., et al. (2013) · Blood · doi:10.1182/blood-2013-04-495341 · Cited by 79
Borge, M., Almejún, M. B., Podaza, E., Colado, A., Grecco, H. F., Cabrejo, M., Bezares, R. F., Giordano, M., & Gamberale, R. (2015) · Haematologica · doi:10.3324/haematol.2014.119669 · Cited by 72
Maffei, R., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0157-x · Cited by 63
Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia
Parseval, L. M., Weiss, L., DeLap, R. J., Knight, R., & Zeldis, J. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2141 · Cited by 60
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Wiestner, A. U. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.88.3801172 · Cited by 59
Seymour, J. F., Davids, M. S., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Huang, D. C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7015 · Cited by 58
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
Bauer, K. H., Rancea, M., Roloff, V., Elter, T., Hallek, M. J., Engert, A., & Skoetz, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008079.pub2 · Cited by 57
Self-citationJain, P., Keating, M. J., Wierda, W. G., Sivina, M., Thompson, P. A., Ferrajoli, A., Estrov, Z. E., Kantarjian, H. M., O'Brien, S. M., & Burger, J. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1948 · Cited by 57
Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia
Seiffert, M., Dietrich, S., Jethwa, A., Glimm, H., Lichter, P., & Zenz, T. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.631638 · Cited by 56
Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia
Hagemeister, F. C. (2010) · Drugs · doi:10.2165/11532180-000000000-00000 · Cited by 51
Purine Antagonists for Chronic Lymphocytic Leukaemia
Steurer, M., Pall, G., Richards, S. M., Schwarzer, G., Bohlius, J., & Greil, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004270.pub2 · Cited by 50
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner, A. U. (2012) · PubMed · doi:10.1182/asheducation-2012.1.88 · Cited by 46
The Role of Minimal Residual Disease Measurements in the Therapy for CLL
Böttcher, S., Hallek, M. J., Ritgen, M., & Kneba, M. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.01.005 · Cited by 44
Self-citationGalletti, G., Caligaris‐Cappio, F., & Bertilaccio, M. T. S. (2016) · Leukemia · doi:10.1038/leu.2016.261 · Cited by 40
Maurer, C., Pflug, N., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Groß-Ophoff-Müller, C., Langerbeins, P., Fink, A., Eichhorst, B. F., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12714 · Cited by 20
Self-citationMaddocks, K. J., Wei, L., Rozewski, D. M., Jiang, Y., Zhao, Y., Adusumilli, M., Pierceall, W. E., Doykin, C., Cardone, M. H., Jones, J. A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23946 · Cited by 18
FCA: Forget Chemoimmunotherapy with Alemtuzumab?
Hallek, M. J. (2012) · Blood · doi:10.1182/blood-2012-04-413096 · Cited by 8
Self-citation
Cited by
Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25638 · Cited by 473
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00163 · Cited by 374
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Valsecchi, R., Coltella, N., Magliulo, D., Bongiovanni, L., Scarfò, L., Ghia, P., Ponzoni, M., & Bernardi, R. (2020) · Open Biology · doi:10.1098/rsob.190262 · Cited by 12
Metadata
- Authors
- Hallek, M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2017-08-07
- Volume
- 92
- Issue
- 9
- Pages
- 946-965
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2744781811
- Cited by
- 282
- References
- 151
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.